Can-Fite BioPharma (CANF) reported Q3 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $613 thousand versus the consensus estimate of $300 thousand.
Can-Fite BioPharma (CANF) reported Q3 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $613 thousand versus the consensus estimate of $300 thousand.